SEARCH IN BRIEF

 
Dempsey joins Nightingale

Leading science architect, Paul Dempsey, is to join Nightingale Associates as the new board-level Science Development Director this month.

Specialising in the pharmaceutical and science sector, Dempsey previously worked for CBRE, Pfizer and Bovis Lend Lease Pharmaceutical. His addition to Nightingale Associates, a leading architectural practice specialising in health, education and science buildings, aims to build upon the practice’s accomplishments within the science sector, helping to promote the company’s knowledge and innovation.

Dempsey said: “I am delighted to be joining Nightingale Associates to help further expand the excellent track record it already has in the science sector. My appointment is intended to boost the science capability with our existing clients and to help develop future work in new and exciting industry sectors.”

Dempsey was recognised as a pioneer and leader of ‘Lab of the Future’ projects, was awarded the prestigious William E Upjohn prize for innovation, and was the first non-scientist award winner in Pfizer’s history for his influential role on the Pfizer FlexiLab projects.

Starting in mid-September Dempsey will be based in Nightingale Associates’ London office.

IN BRIEF
Wednesday 16 September 2009
Callison becomes latest firm to join ARCADIS
Fri 22 Aug 2014
HOK to acquire 360 Architecture
Fri 22 Aug 2014
Interview: Laurinda Spear, ArquitectonicaGEO
Fri 22 Aug 2014
Promotions at Perkins Eastman and affiliate companies
Fri 15 Aug 2014
New York architect picked to lead Columbia University’s School of Architecture
Thu 14 Aug 2014
Giam Swiegers to become CEO of Aurecon as of 1 February 2015
Thu 14 Aug 2014
NEON to design RIBA Lounge at MIPIM UK
Wed 13 Aug 2014
WOHA to design Trump Tower Mumbai
Wed 13 Aug 2014